Skip to Content
scroll

Opthea Ltd (OPT)

ASX.OPT $1.02

20 MINUTE DELAYED

14 DAYS FREE ACCESS

Join Market Matters and get full access
to all our Opinion + Action

LEARN MORE

OPT $1.02

20 MINUTE DELAYED

TODAY

0.49 %

1 YEAR RETURN

0.00%

VOLUME

1,928,573

DIV YIELD

0%

PE RATIO

0.00

52 WEEK RANGE

0.34

1.17

ANALYSIS

i

SHARE PRICE ACTIVITY
Last (Price)

1.02

Change

0.01 (0.49)

Bid / Ask

1.01 - 1.03

Volume

1,928,573

Turnover

1,954,608

Open

1.01

Day Range

1.00 - 1.03

VWAP

1.01

Prev Close

1.02

Last Trade

13/02 4:10pm (AEST)

i

KEY INFORMATION
Sector

Shares Issued

NTA/Share

0.00

Last Dividend

0.00

Dividend Ex Date

0

Dividend Pay Date

0

i

BROKER CALLS

current

Mean

0.00

Target Price

0.00

i

CURRENT ()
Revenue

0.13

EBITDA

-191.74

Profit

-220.24

Earnings Per Share (EPS)

0

Dividend Per Share (DPS)

0

Yield %

0.00

Market Cap

0

Price to Earnings Ratio (P/E)

0

i

TARGET PRICE FORECAST

i

ESTIMATES ()
Revenue

0.13

EBITDA

-167.74

Profit

-217.15

Earnings Per Share (EPS)

-0.16

Dividend Per Share (DPS)

0.00

i

BROKER CONSENSUS RECOMMENDATION

BUY

SELL

Target Price

0.00

Lt Growth Rate

0.00

Recommendation ()

0.00
image description

Business Summary

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing novel therapies to treat highly prevalent and progressive retinal eye diseases including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s lead product candidate OPT-302 is in pivotal Phase III clinical trials and being developed for use in combination with anti- Vascular Endothelial Growth Factor (VEGF-A) monotherapies to achieve broader inhibition of the VEGF family. OPT-302 has the potential to address the unmet medical need of wet age-related macular degeneration (AMD) and diabetic macular edema (DME) patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. The Company is advancing the clinical development of OPT-302 in wet AMD and DME clinical trials.

image description

Only available to Members

Take a free 14 day Market Matters trial – full access to all our reports, portfolios, positions, buy and sell recommendations. Access the latest views on the latest developments from professional money managers. It's free and no payment details are required
For membership options and pricing. Click here
Back to top